Skip to main content
. 2021 Mar 26;7(13):eabe1682. doi: 10.1126/sciadv.abe1682

Fig. 5. In vivo antitumor effect of CMPX-383B in a MM xenograft model.

Fig. 5

(A) Therapy schedule followed for the treatment of both MM xenograft models. i.v., intravenously. (B) Treatment of NCI-H929 xenograft mice for 14 days with CMPX-383B (n = 10) significantly decreases tumor volume (TV) growth in CMPX-383B–treated mice, compared to vehicle (n = 10, P = 0.002). (C) Treatment of the MOLP-8 xenograft model with CMPX-383B (n = 10) results in a significant decrease in tumor volume growth during the treatment period compared to vehicle (n = 10, P = 0.007), **P ≤ 0.01.